Overview

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Oxaliplatin
Paclitaxel